Abstract
Hepatitis C virus (HCV) therapy will benefit from the preclinical evaluation of direct-acting antiviral (DAA) agents in infectious culture systems that test the effects on different virus genotypes. We developed HCV recombinants comprising the 5'UTR-NS5A (5-5A) from genotypes 1-6 and 2a(JFH1) NS5B-3'UTR, and tested the effects of NS3 protease and NS5A inhibitors on these recombinants.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Gastroenterology |
| Vol/bind | 146 |
| Udgave nummer | 3 |
| Sider (fra-til) | 812-821 |
| Antal sider | 10 |
| ISSN | 0016-5085 |
| DOI | |
| Status | Udgivet - mar. 2014 |